Delivery Order SPE2DB24D1006-SPE2DB25FCEUG
- Not listed
- The Defense Logistics Agency issued a delivery order valued at $7,166.59 to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed-price delivery order, awarded on September 11, 2025, with completion targeted for September 12, 2025, represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The award was made through open competition with no set-aside designation, and performance will be...
- The Defense Logistics Agency awarded a $9,986.88 delivery order to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. The contract, which carries a firm fixed price structure with no set-aside designation, was competitively awarded on September 27, 2025, with an ultimate completion date of September 29, 2025. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $2,569.50 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Mestinon 180 mg Timespan in units of 30, with completion scheduled for September 24, 2025. This firm fixed-price contract represents a non-set-aside competitive award issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $5,285.05 delivery order by the Defense Logistics Agency on June 18, 2025, for Mestinon 180 mg Timespan in quantities of 30. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is scheduled for completion by June 20, 2025. The contract fulfills pharmaceutical supply requirements for federal medical procurement, with performance taking...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units, valued at $4,993.44. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and was awarded on a competitive basis without set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,496.72 to AmerisourceBergen Drug Corp for Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed price, non-set-aside contract was awarded on August 18, 2025, with an ultimate completion date of August 19, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,235.88, is for the supply of 180 mg Mestinon Timespan medication. The contract is a firm fixed-price delivery order with a completion date of March 27, 2025. There is no set-aside designation for this award. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,187.77, is for the delivery of MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of April 4, 2025. This contract award is not associated with a set-aside designation....
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of MESTINON 60 MG TABLET 100S. The contract has a ceiling value of $4,196.48 and an ultimate completion date of May 19, 2025. The contract is not set aside and was competed openly. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $14,166.32 to AmerisourceBergen Drug Corp for the supply of Pyridostigmine Bromide 30 mg tablets with an ultimate completion date of September 19, 2025. This is a firm fixed-price delivery order under a competitively awarded, non-set-aside contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCEUGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,269.88 to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed-price delivery order, issued on June 16, 2025, with an ultimate completion date of June 17, 2025, represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive relationship with the Defense Logistics Agency Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999, which extends through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates consistent capability in fulfilling diverse medical supply needs ranging from specialty medications to generic drugs, positioning it as a key provider for Defense Health Agency requirements and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.3k | 6/16/25 |